Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndromes

#4090

Introduction: In patients with metastatic functional neuroendocrine tumors (NETs), symptoms are, sometimes, not adequately controlled with long-acting somatostatin analogues (LASSAs), so patients need to use boost subcutaneous (sc) octreotide injections (inj) daily. However, this approach is not always effective and convenient for the patients.

Aim(s): To evaluate the efficacy and safety of continuous sc octreotide infusion pump (OIP) in patients with functional NETs and refractory symptoms, despite LASSAs and daily boost sc Octreotide.

Materials and methods: We collected data retrospectively from patients treated in our tertiary centre and focused on clinical outcomes, safety and progression free survival (PFS). Symptoms’ improvement of more than 50%, was defined as “symptomatic response” (SR). Patients’ follow-up was complete.

Conference:

Presenting Author: Thuringer J

Authors: Thuringer J, Parker G, Sarma A, Hayes A, Mandair D,

Keywords: carcinoid syndrome, VIPoma, Octreotide, pump, refractory, subcutaneous,